Online
|
|
CIPLA AND SOME OTHER BULLISH STOCKS
Posted by :
rupesh711in
CIPLA
HAS MADE Sep 30, 2009 Triple Moving Average Crossover (4-day 9-day 18-day) Short-Term Bullish 279.50 n/a
Sep 29, 2009 Symmetrical Continuation Triangle (Bullish) Intermediate-Term Bullish AT-279.60
TRGTS-306.00 - 315.00
Usher Agro
HAS MADE Sep 29, 2009 Symmetrical Continuation Triangle (Bullish) Intermediate-Term BullishAT- 41.25
Sep 29, 2009 Commodity Channel Index Short-Term Bullish 41.25
Sep 29, 2009 Bottom Triangle Intermediate-Term Bullish 41.25 Sep 25, 2009 Price Crosses Moving Average (200-day) Long-Term Bullish 40.70
TRGTS-47.25 - 48.75 -53.00 - 55.00
Karuturi Global
HAS MADE Sep 29, 2009 Ascending Continuation Triangle Intermediate-Term Bullish AT-17.35
TRGTS-19.60 - 20.20
Glory Polyfilms
HAS MADE Sep 29, 2009 Bottom Triangle Intermediate-Term Bullish AT-27.05
Sep 29, 2009 Triple Moving Average Crossover (4-day 9-day 18-day) Short-Term Bullish AT-27.05
Sep 25, 2009 Price Crosses Moving Average (21-week)W Intermediate-Term Bullish AT-25.90
TRGTS-33 - 34.50
HFCL Infotel
HAS MADE Sep 29, 2009 Price Crosses Moving Average (21-day) Short-Term Bullish AT-6.81
Sep 29, 2009 Diamond Bottom Intermediate-Term Bullish AT-6.81
TRGTS- 8.50 - 8.90
Hindustan Unilever
HAS MADE Sep 29, 2009 Price Crosses Moving Average (21-day) Short-Term Bullish AT-262.65
Sep 29, 2009 Symmetrical Continuation Triangle (Bullish) Intermediate-Term Bullish AT-262.65
TRGTS- 314 - 326
Rural Electrification
HAS MADE Sep 29, 2009 Symmetrical Continuation Triangle (Bullish) Intermediate-Term Bullish AT-200.20 TRGTS-226 - 233
New Delhi Television
HAS MADE Sep 29, 2009 Symmetrical Continuation Triangle (Bullish) Intermediate-Term Bullish AT-169.40
TRGTS-202 - 210 - 213 - 224
ONGC
HAS MADE Sep 29, 2009 Continuation Diamond (Bullish) Long-Term Bullish AT-1186.15
TRGTS-1410 - 1462
Gujarat State Fertilizers & Chemicals
HAS MADE Sep 29, 2009 Flag (Bullish) Short-Term Bullish AT-172.20
TRGTS-208 - 217
Tata Chemicals
HAS MADE Sep 29, 2009 Ascending Continuation Triangle Intermediate-Term Bullish AT-278.90
TRGTS- 350 - 367
TVS Motor
HAS MADE Sep 29, 2009 Symmetrical Continuation Triangle (Bullish) Intermediate-Term Bullish AT-61.35
TRGTS- 80 - 84
Mercator Lines
HAS MADE Sep 29, 2009 Continuation Diamond (Bullish) Intermediate-Term Bullish AT-62.00
Sep 29, 2009 Symmetrical Continuation Triangle (Bullish) Intermediate-Term Bullish AT-62.00
Sep 30, 2009 Ascending Continuation Triangle Intermediate-Term Bullish AT-62.90
TRGTS- 72 - 75- 75 - 78- 83 - 88
Anant Raj Industries
HAS MADE Sep 29, 2009 Symmetrical Continuation Triangle (Bullish) Intermediate-Term Bullish AT-146.40
TRGTS-172 - 180
...
NSE Announcements on Cipla
Posted by : MMB MessengerCipla Ltd. has informed the Exchange that "The duly authorized Committee of Directors of the Company at its meeting held today i.e. on September 29, 2009 , at Hyderabad has issued and allotted 2,56,30,000 fully paid-up equity Shares of Rs. 2 each ("Equity Share") at an issue price of Rs.263.75 per Equity Share (including a premium of Rs.261.75 per Equity Share) aggregating to Rs.6,75,99,12,500 to qualified institutional bidders by way of a qualified institutions placement in terms of Chapter VIII of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009"....
BSE Announcements on Cipla
Posted by : MMB MessengerCipla Ltd has informed BSE that the duly authorised Committee of Directors (CoD) of the Company at its meeting held on September 29, 2009, has issued and allotted 2,56,30,000 fully paid-up equity shares of Rs 2 each ("Equity Shares") at an issue price of Rs 263.75 per Equity Share (including a premium of Rs 261.75 per Equity Share) aggregating to Rs 6,75,99,12,500 to qualified institutional bidders by way of a qualified institutions placement in terms of Chapter VIII of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009. ...
Warren Buffet says that:
Posted by : jalunm
Warren Buffet says that:
“An investor should ordinarily hold a small piece of an outstanding business with the same tenacity that an owner would exhibit if he owned all of that business.”
"You are neither right nor wrong because the crowd disagrees with you. You are right because your data and reasoning are right."
He made all his fortune followed by this philosophy....
Hence, I am only recommending those selected small cap scripts which are very cheap and performing companies rather over a valued mid cap and big cap,
Do not enter if you are a trader, only those long term investors can gain from those scripts.
Keep in mind, Only invest do not trade, and sleep well and forget until 1 to 2 years , your capital might increase to 2 to 3 times.
Suggested : (Many bad gossip already spread over the market, forget about.)
Now it is your choice.
IDBI Bank
VITLINFO
KSK
IBN18
Mahindra Satyam
Jalu
jalunm@yahoo.c o.i n...
Buy Cipla
Posted by : rajkishore420Buy Cipla. There is a positive breakout on this counter on a short term basis....
NSE Announcements on Cipla
Posted by : MMB MessengerCipla Ltd. has informed the Exchange that "The duly authorized Committee of Directors of the Company at its meeting held today i.e. on September 24, 2009 has decided to close the bid period and has approved issuance of 2,56,30,000 Equity Shares of Rs. 2 each of the Company at a price of Rs. 263.75 per Equity Share (including a premium of Rs. 261.75 per equity share) under the QIP issue, aggregating to Rs. 6,75,99,12,500/-. The Committee has also approved the Placement Document in respect of the Equity Shares proposed to be issued as aforesaid."...
[Investors Please Listen] Cipla has completed a QIP of around Rs 670 cr. Impact positive on the company
Posted by :
basit222Though this QIPO will result in dilution in earnings to the extent of 3-4% we believe the net impact will be positive for the company as it can generate better returns from the incremental capex. The company has plans of capex of around Rs 500-600 cr per annum. Company expects to generate ROA of 1.5-1.8 times thus it can improve its return ratios. Cipla has debt of around Rs 900 cr at the end of FY09 Pre dilution our EPS estimates for Cipla are Rs 12.9 for FY10 & Rs 15.2 for FY11. At the CMP the stock is trading at 17x FY11 EPS....
BSE Announcements on Cipla
Posted by : MMB MessengerCipla Ltd has informed BSE that the duly authorized Committee of Directors (CoD) of the Company at its meeting held on September 24, 2009, has decided to close the bid period and has approved issuance of 2,56,30,000 Equity Shares of Rs. 2 each of the Company at a price of Rs. 263.75 per Equity Share (including a premium of Rs. 261.75 per equity share) under the QIP issue, aggregating to Rs. 6,75,99,12,500/-. The Committee has also approved the Placement Document in respect of the Equity Shares proposed to be issued as aforesaid....
Is it right time to enter Cipla?
Posted by :
crusader55Cipla always seems to go opposite the market! Is it a good level to enter now for long term - 2 year - investment time frame?...
Why CIPLA is not peroming well in Market
Posted by :
akashatulWhy CIPLA is lossing rate day by day if market in Good Position? What will be Rate of Cipla with 1-2 month?...
Buy Cipla for Long Term
Posted by : sudhi_shiva
Cipla`s Net Profit increased by 194.93 Crores (1286.71 Vs 1091.78). Visit their website and have a look at financials!
Growth in profit of this company is amazing since year 2000 and I think Cipla will be a very good stock for long term investers.
Also exports makes this company famous around the globe.
Happy Investing!...
Cipla inks long-term pact with Pharmaceutical major Meda
Posted by : SONOM_2005
Pharmaceutical major Cipla has signed a long-term collaboration agreement with Meda AB, a Sweden-based specialty pharmaceutical company, to develop and market an anti-allergic rhinitis drug for various global markets.
Under the arrangement, domestic pharmaceutical company will manufacture the drug, which will treat an ailment that causes a runny nose, while Meda will market the product in Europe, Japan, Brazil, South Korea and Australia.
Meda would pay Cipla $5 million upon regulatory approval in the first market and up to $10 million as other milestone payments.
According to sources, the drug is currently in the final phase of human clinical trials (Phase III) and the remaining clinical studies are expected to be complete during the second half of 2010. ...
The undertone of Indian markwet is Bulish. This is a good scrip and one can go and buy this for medium term for appreciation of 30% to 40%.
...
USFDA had issued warning letters to Cipla on finding deficiencies in Bangalore facility.
Posted by : basit222
India’s top generic maker Cipla’s pharmaceuticals manufacturing facility in Bangalore has been cleared of alleged violations in current good manufacturing practices (cGMP) norms by US FDA.
USFDA officials had issued warning notices to the Mumbai-based Cipla for deficiencies in manufacturing practices following their inspection in its Bangalore facility.
USFDA inspection team has reportedly found out a few violations in the manufacturing norms mandated by the agency. Subsequently, USFDA asked Cipla to submit report on the corrective measures within 30 days of serving the warning notice, in April.
Cipla has addressed all the manufacturing deficiencies pointed out by the USFDA and submitted a report within the time-frame as required by FDA 483s. Following this, Cipla received an official communication about the approval from the USFDA about a month back, it is learnt.
USFDA periodically inspects all plants approved by the agency to ensure that drugs made at these facilities are safe to be sold in the US. For plants in India, the FDA usually makes a biannual inspection.
Cipla is currently the top generic company in India. Cipla also exports APIs and formulations to several regulated and semi-regulated markets including US, UK and South Africa.
In May, Cipla received approvals from USFDA for tenofovir disoproxil fumarate tablets. The drug is used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Cipla is allowed to sell the drug in tablet form in dosages of 300 milligram under the President’s Emergency Plan for AIDS Relief program.
Tenofovir disoproxil fumarate tablets are the generic version of Gilead Sciences Inc.’s (GILD) Truvada.
Similarly, Cipla received approvals for stavudine and levetiracetam from the United States Food and Drug Administration (USFDA), in March.
USFDA’s action against Cipla is the latest in a series of inspections and warning letters issued by the regulator against Indian drug makers....
